CMP DEV LLC
PharmaCMP DEV LLC is a pharmaceutical company focused on Cardiovascular, Respiratory, Metabolic. Key products include ATORVALIQ.
CMP DEV LLC's Key Drugs
CMP DEV LLC's core commercial portfolio centers on ATORVALIQ, NORLIQVA, CAROSPIR, spanning Cardiovascular and Respiratory — its most strategically important drugs approved in the last 15 years.
Myocardial Infarction
Hypertension
Heart Failure
Pulmonary Arterial Hypertension
Hypophosphatemia
CMP DEV LLC's Recent FDA Approvals
New NDA/BLA approvals for CMP DEV LLC over the last two years — novel drugs only, excluding generics and label supplements.
CMP DEV LLC's Therapeutic Areas
CMP DEV LLC's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CMP DEV LLC's Top Competitors
CMP DEV LLC's closest competitors by therapeutic-area and drug-target overlap include Merck, AstraZeneca, and Boehringer Ingelheim. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CMP DEV LLC Pipeline Snapshot
Active clinical trials for CMP DEV LLC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ATORVALIQ leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling